Haisley Kelly R, Abdelmoaty Walaa F, Dunst Christy M
The Ohio State University, Wexner Medical Center, 410 W 10th Ave, Columbus, OH, 43210, USA.
Providence Portland Medical Center, 4805 NE Glisan St, Portland, OR, 97213, USA.
J Gastrointest Surg. 2021 Jan;25(1):9-15. doi: 10.1007/s11605-019-04506-4. Epub 2020 Feb 19.
Esophagectomy is a fundamental step to achieve long-term disease-free survival in esophageal cancer. While various approaches have been described, there is no consensus on the single best technique to optimize operative and oncologic outcomes. We aim to report the modern experience with laparoscopic transhiatal esophagectomy (LTHE) for invasive adenocarcinoma.
We reviewed all patients who underwent LTHE with extended lymph node dissection for distal esophageal adenocarcinoma (EAC) at our institution between 2007 and 2016. Pre-operative characteristics, operative details, postoperative complications, and long-term outcomes were tracked by review of the electronic medical record and patient surveys. Survival rates were calculated with Kaplan-Meier curves.
Eighty-two EAC patients underwent LTHE during the study period (84% male, mean age 65, mean BMI 27.8, large). Most patients were clinical stage III (42.7%) and 68.3% had received neoadjuvant chemoradiation (nCRT). Laparoscopy was successful in 93.9%, with five cases requiring conversion to open (6.1%). The median lymph node harvest was 19. Overall complication rate (major and minor) was 45.5% and ninety-day mortality was 4%. Overall 5-year survival was 52% (77% for stage 1, 57% for stage 2, 37% for stage 3).
Laparoscopic transhiatal esophagectomy has an important role in current esophageal cancer treatment and can be performed with curative intent in patients with distal esophageal tumors. In addition to the well-known advantages of laparoscopy, the increased mediastinal visibility and a modern focus on oncologic principles seem to have a positive impact on cancer survival compared to the open transhiatal approach.
食管切除术是实现食管癌长期无病生存的基本步骤。虽然已经描述了多种手术方法,但对于优化手术和肿瘤学结局的最佳单一技术尚无共识。我们旨在报告腹腔镜经裂孔食管切除术(LTHE)治疗浸润性腺癌的现代经验。
我们回顾了2007年至2016年间在本机构接受LTHE并扩大淋巴结清扫术治疗远端食管腺癌(EAC)的所有患者。通过查阅电子病历和患者调查来跟踪术前特征、手术细节、术后并发症和长期结局。用Kaplan-Meier曲线计算生存率。
在研究期间,82例EAC患者接受了LTHE(84%为男性,平均年龄65岁,平均BMI 27.8,体型较大)。大多数患者为临床Ⅲ期(42.7%),68.3%接受了新辅助放化疗(nCRT)。腹腔镜手术成功率为93.9%,5例需转为开放手术(6.1%)。中位淋巴结清扫数为19枚。总体并发症发生率(主要和次要)为45.5%,90天死亡率为4%。总体5年生存率为52%(Ⅰ期为77%,Ⅱ期为57%,Ⅲ期为37%)。
腹腔镜经裂孔食管切除术在当前食管癌治疗中具有重要作用,对于远端食管肿瘤患者可进行根治性手术。除了腹腔镜手术众所周知的优点外,与开放经裂孔手术相比,纵隔视野的增加以及对肿瘤学原则的现代关注似乎对癌症生存有积极影响。